ADAM-21 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAM-21 (UniProt Q9UKJ8), expressed in HEK293 cells. Suited for metalloproteinase activity studies, inhibitor profiling, and antibody validation using matched TPB antibody RP-ADAM21.
Expression system
HEK293
Cat. #
REC-ADAM21

In stock

SKU
REC-ADAM21
$498.00

Target Overview

ADAM-21 (UniProt Q9UKJ8; gene ADAM21) is a member of the ADAM (A Disintegrin And Metalloproteinase) family of zinc-dependent metalloproteinases. The full-length human protein spans 722 amino acids and is classified under EC 3.4.24.-. Like other ADAM family members, the domain architecture includes a signal peptide, propeptide, metalloproteinase catalytic domain, disintegrin domain, cysteine-rich region, and a transmembrane anchor that localises the mature protein to the cell membrane. This recombinant is produced in HEK293 mammalian cells, an expression system that supports the glycosylation and folding events expected for a type I transmembrane metalloproteinase. Mammalian-cell expression is particularly relevant for ADAM family members, where correct disulfide bonding within the cysteine-rich domain influences protein conformation and activity. Researchers use this recombinant in several contexts. In metalloproteinase activity assays, it provides a defined, human-sequence enzyme source for substrate cleavage studies. In inhibitor profiling experiments, it serves as the target enzyme for IC50 determination against hydroxamate-class or other metalloproteinase inhibitor chemotypes. Because the recombinant is produced with a human sequence, it is well-suited as a positive control antigen in Western blot and ELISA-based antibody validation — researchers needing an antigen standard for the Triple Point Biologics anti-ADAM21 antibody (SKU: RP-ADAM21) can use this recombinant directly. The protein is also applicable to binding studies examining interactions between the disintegrin domain and candidate integrin partners, and to proteomic workflows requiring a reference standard for mass spectrometry-based quantification of ADAM-21 in complex biological matrices.

Background

ADAM-21 belongs to the ADAM family, a group of multidomain transmembrane and secreted metalloproteinases that regulate ectodomain shedding, cell adhesion, and extracellular matrix remodelling across a wide range of tissues. The family is broadly studied for roles in nervous system development, reproductive biology, and cancer cell biology (Hsia et al., 2019, Cell Mol Life Sci). In reproductive biology, ADAM-21 expression has been documented in testis and sperm, and the protein has been proposed to participate in sperm maturation and fertilisation-related membrane interactions. A mouse knockout study by Chen et al. (2021, PeerJ) found that Adam21-deficient male mice remained fertile under standard housing conditions, suggesting either functional redundancy with other ADAMs in murine reproduction or a species-specific role. Consistent with the reproductive biology angle, a 2025 proteomic study of sperm from varicocele patients undergoing sclero-embolisation (Milardi et al., 2025, Proteomes) identified ADAM-21 as part of a broader remodelling of the sperm proteome associated with changes in semen quality, placing ADAM-21 within a network of sperm surface proteins of interest for male reproductive research. Beyond reproduction, ADAM-21 has been characterised as a research target in oncology. Honda et al. (2017, Sci Rep) reported that ADAM-21 is overexpressed in hepatocellular carcinoma (HCC) tumour tissue relative to adjacent non-tumour liver, and that elevated ADAM-21 expression correlated with tumour cell motility and metastatic behaviour in cell-based models, as well as with poorer patient outcomes in clinical cohorts. This work positions ADAM-21 as a candidate marker and potential functional mediator in HCC biology, studied using standard migration, invasion, and gene-knockdown assays. Separately, phenotype-based single-cell sequencing of CD133-positive cancer stem cell populations has detected ADAM-21 transcript among differentially expressed genes, suggesting a broader relevance to cancer stem cell heterogeneity research (Min et al., 2021, Biochem Biophys Res Commun). The recombinant protein described here provides a defined human-sequence reagent for researchers investigating ADAM-21 function in any of these contexts — reproductive cell biology, hepatocellular carcinoma models, or ADAM family inhibitor programmes. Researchers requiring an antibody counterpart for immunodetection or co-validation experiments can pair this recombinant with the Triple Point Biologics anti-ADAM21 antibody (SKU: RP-ADAM21).

Applications

  • Metalloproteinase substrate cleavage activity assay (fluorogenic or quenched-peptide substrate format)
  • Inhibitor IC50 determination against hydroxamate-class or small-molecule metalloproteinase inhibitor panels
  • Antibody validation positive control for Western blot using matched TPB anti-ADAM21 antibody (RP-ADAM21)
  • Antigen standard for ELISA-based detection and antibody titration experiments
  • Disintegrin domain–integrin binding interaction studies by surface plasmon resonance or bio-layer interferometry
  • Reference standard for mass spectrometry-based quantification of ADAM-21 in sperm or tumour cell proteomes
  • Recombinant antigen for immunisation and hybridoma screening workflows

References

  1. Milardi D et al. Molecular Remodeling of the Sperm Proteome Following Varicocele Sclero-Embolization: Implications for Semen Quality Improvement. Proteomes. 2025. doi:10.3390/proteomes13030034. PMID: 40700278
  2. Chen Y et al. Adam21 is dispensable for reproductive processes in mice. PeerJ. 2021. doi:10.7717/peerj.12210. PMID: 34631320
  3. Min DW et al. Phenotype-based single cell sequencing identifies diverse genetic subclones in CD133 positive cancer stem cells. Biochem Biophys Res Commun. 2021. doi:10.1016/j.bbrc.2020.09.005. PMID: 32958251
  4. Hsia HE et al. Functions of 'A disintegrin and metalloproteases (ADAMs)' in the mammalian nervous system. Cell Mol Life Sci. 2019. doi:10.1007/s00018-019-03173-7. PMID: 31236626
  5. Honda H et al. Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma. Sci Rep. 2017. doi:10.1038/s41598-017-15800-z. PMID: 29138461

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type I transmembrane; cell surface; Golgi → endosomes

Frequently Asked Questions

What is the expected molecular weight of recombinant ADAM-21 on SDS-PAGE or Western blot?

The full-length human ADAM-21 protein (UniProt Q9UKJ8) has a calculated molecular weight of approximately 82 kDa based on its 722-amino-acid sequence. Because this recombinant is expressed in HEK293 cells, N-linked glycosylation is expected to shift the apparent MW on SDS-PAGE to roughly 90–100 kDa under reducing conditions. The precise band position can vary slightly by gel system and percentage. If you are running a Western blot positive control alongside our matched antibody RP-ADAM21, load 50–100 ng per lane and expect a diffuse band in the 90–100 kDa range consistent with glycoprotein migration.

Which processing form of ADAM-21 is present in this recombinant — full-length, prodomain-cleaved, or ectodomain only?

This recombinant corresponds to the mature, prodomain-processed ectodomain of human ADAM-21, encompassing the metalloproteinase, disintegrin, and cysteine-rich domains. The signal peptide and propeptide are removed during HEK293 expression and secretory processing, yielding an active enzyme fragment rather than the full 722-residue precursor. The transmembrane anchor is not included, which allows purification from the conditioned medium. This soluble, processed form is the relevant species for most in vitro metalloproteinase activity and binding assays.

What substrates can I use in an ADAM-21 metalloproteinase activity assay?

ADAM-21 is a zinc-dependent metalloproteinase (EC 3.4.24.-) and can be assayed using generic ADAM-family fluorogenic peptide substrates such as Mca-PLAQAV-Dpa-RSSSR-NH2 or related quenched fluorescent peptides based on the consensus ADAM cleavage motif. Monitor fluorescence at Ex/Em 320/405 nm. Because ADAM-21's specific endogenous substrates in vivo remain incompletely characterized, fluorogenic peptide substrates provide a practical proxy for measuring catalytic competence. Include a broad-spectrum metalloproteinase inhibitor such as GM6001 (10 µM) as a negative control to confirm that signal is zinc-dependent and proteinase-specific.

What buffer conditions are recommended for ADAM-21 activity assays, and does it need calcium?

The recombinant is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 — the calcium is included because ADAM family metalloproteinases require Ca²⁺ for structural stability of the catalytic domain. For activity assays, dilute into a reaction buffer of 25–50 mM Tris-HCl pH 7.4–7.5, 150 mM NaCl, 5–10 mM CaCl2, 0.05% Brij-35. Omitting calcium markedly reduces catalytic activity. Keep assay pH between 7.0 and 7.8; activity drops sharply outside this range. Pre-equilibrate protein and substrate to 37°C before combining to minimize lag-phase variability.

What starting enzyme concentration should I use for an ADAM-21 fluorogenic peptide activity assay?

A practical starting point is 1–5 nM recombinant ADAM-21 per reaction, with fluorogenic substrate at 10–20 µM. At these concentrations, substrate is well below saturation (Km for ADAM-family peptide substrates typically falls in the 5–50 µM range), keeping conditions in the linear, kinetically meaningful regime. If you are running inhibitor IC50 experiments, fix enzyme concentration at 2 nM, titrate inhibitor across at least eight concentrations spanning three orders of magnitude, and allow 10 minutes of enzyme-inhibitor pre-incubation at 37°C before adding substrate. Verify linearity of the fluorescence signal over at least 30 minutes before calculating initial velocity.

Can I use recombinant ADAM-21 as a positive control on a Western blot when validating the RP-ADAM21 antibody?

Yes — this is a primary use case. Load 50–100 ng of recombinant ADAM-21 (REC-ADAM21) per lane alongside your cell lysate samples. After transfer and blocking, use the matched rabbit polyclonal antibody RP-ADAM21 (see /anti-adam-21-rabbit-polyclonal-antibody) at a recommended starting dilution of 1:500–1:1000 in 5% non-fat milk/TBST. Expect a band at approximately 90–100 kDa for the recombinant and a band at 90–100 kDa (or higher if full-length precursor is present) in ADAM-21-expressing cell lysates. The recombinant and antibody are produced and validated in the same laboratory, eliminating the guesswork around epitope compatibility.

How much recombinant ADAM-21 should I load for a Western blot positive control, and will it over-saturate the blot?

50 ng is sufficient for a clean, non-saturating positive control band with the RP-ADAM21 antibody under standard ECL detection. If you are using a high-sensitivity HRP substrate (e.g., femtogram-range detection systems), reduce loading to 10–25 ng to avoid blooming. Because the recombinant is >90% pure by SDS-PAGE, background bands are minimal and will not confound interpretation. Run it in a lane adjacent to — not co-mingled with — your experimental lysates so that antibody titration across the blot remains consistent. A 10% SDS-PAGE gel resolves the ~90–100 kDa band cleanly away from common contaminants.

How should I store and handle recombinant ADAM-21 to maintain activity, and what is its shelf life?

Store at −20°C in the single-use aliquots provided. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2) is formulated to stabilize the metalloproteinase domain through freeze-thaw. Repeated freeze-thaw cycles progressively reduce activity — once an aliquot is thawed, keep it on ice and use within 4–6 hours. Shelf life is 12 months from the date of receipt when stored correctly. For dilutions below 10 µg/mL, add carrier protein (0.1% BSA, protease-free) to prevent surface adsorption losses. Do not add EDTA or EGTA to working buffers; chelation of Zn²⁺ and Ca²⁺ will inactivate the enzyme irreversibly.

Validation imagery coming soon

Western blot validation figures for REC-ADAM21 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →